keyword
MENU ▼
Read by QxMD icon Read
search

Gemcitabine

keyword
https://www.readbyqxmd.com/read/29164423/successful-radical-surgical-resection-of-initially-unresectable-intrahepatic-cholangiocarcinoma-by-downsizing-chemotherapy-with-gemcitabine-plus-cisplatin-a-case-report
#1
Ryosuke Takayanagi, Shigetsugu Takano, Kensuke Sugiura, Hideyuki Yoshitomi, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Atsushi Kato, Masaru Miyazaki, Masayuki Ohtsuka
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a subtype of biliary tract cancer (BTC). Recently, downsizing chemotherapy has been applied to initially unresectable BTCs, including ICC. CASE PRESENTATION: We report a case of liver resection in a 23-year-old woman who was diagnosed with initially unresectable ICC attached to the inferior vena cava, with portal vein (PV) cavernous transformation. Positron emission tomography (PET) showed fluorodeoxyglucose (FDG) uptake in the para-aortic lymph nodes...
November 21, 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/29164059/intravesical-gemcitabine-versus-intravesical-bacillus-calmette-gu%C3%A3-rin-for-the-treatment-of-non-muscle-invasive-bladder-cancer-an-evaluation-of-efficacy-and-toxicity
#2
Thiru Prasanna, Paul Craft, Gayathri Balasingam, Hodo Haxhimolla, Ganes Pranavan
Background: Intravesical Bacillus Calmette-Guérin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common. Objectives: To compare the efficacy and toxicity of intravesical BCG and gemcitabine in the treatment of NMIBC. Methods: Retrospective data were collected in the region of Canberra, Australia from January 2010 to December 2015...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29163992/cd56-negative-aggressive-nk-cell-leukemia-relapsing-as-multiple-cranial-nerve-palsies-case-report-and-literature-review
#3
M Guerreiro, F Príncipe, M J Teles, S Fonseca, A H Santos, E Fonseca, P Gomes, C Marques, M Lima
Background: Aggressive natural killer cell leukemia (ANKL) is extremely rare and habitually manifests as a systemic disease with multiorgan failure that rapidly evolves to death. The neoplastic natural killer (NK) cells usually harbor the Epstein-Barr virus (EBV) with a latent viral infection pattern type II; they often have a cytoplasmic CD3ε(+) and surface CD3(-), CD2(+), and CD56(+) immunophenotype, and they show complex genetic abnormalities affecting multiple tumor suppressor genes and oncogenes...
2017: Case Reports in Hematology
https://www.readbyqxmd.com/read/29163820/role-of-drug-dependent-transporter-modulation-on-the-chemosensitivity-of-cholangiocarcinoma
#4
Nerea Urtasun, Clara Boces-Pascual, Loreto Boix, Jordi Bruix, Marçal Pastor-Anglada, Sandra Pérez-Torras
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with limited therapeutic options. Curative therapy is limited to surgery whereas chemotherapy treatments are the election option for unresectable or metastatic cholangiocarcinoma. Cisplatin plus gemcitabine is the reference chemotherapy regimen, albeit the contribution to the median overall survival barely reaches one year. Drug transporters are undoubtedly a limiting step for drug bioavailability and have been clearly related to chemoresistance...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29163814/multivalent-cationic-pseudopeptide-polyplexes-as-a-tool-for-cancer-therapy
#5
Zoi Diamantopoulou, Maud-Emmanuelle Gilles, Maha Sader, Mélissande Cossutta, Benoit Vallée, Claire Houppe, Damien Habert, Blandine Brissault, Eric Leroy, Federica Maione, Enrico Giraudo, Damien Destouches, Jacques Penelle, José Courty, Ilaria Cascone
In this study, a novel anticancer reagent based on polyplexes nanoparticles was developed. These nanoparticles are obtained by mixing negatively charged polyelectrolytes with the antitumour cationically-charged pseudopeptide N6L. Using two in vivo experimental tumor pancreatic models based upon PANC-1 and mPDAC cells, we found that the antitumour activity of N6L is significantly raised via its incorporation in polyplexed nanoparticles. Study of the mechanism of action using affinity isolation and si-RNA experiments indicated that N6L-polyplexes are internalized through their interaction with nucleolin...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29163795/oral-4-n-stearoyl-gemcitabine-nanoparticles-inhibit-tumor-growth-in-mouse-models
#6
Caixia Wang, Yuanqiang Zheng, Michael A Sand Oval, Solange A Valdes, Zhe Chen, Dharmika S Lansakara-P, Maolin Du, Yanchun Shi, Zhengrong Cui
In spite of recent advances in targeted tumor therapy, systemic chemotherapy with cytotoxic agents remains a vital cancer treatment modality. Gemcitabine is a nucleoside analog commonly used in the treatment of various solid tumors, but an oral gemcitabine dosage form remain unavailable. Previously, we developed the 4-(N)-stearoyl gemcitabine solid lipid nanoparticles (GemC18-SLNs) by incorporating 4-(N)-stearoyl gemcitabine (GemC18), an amide prodrug of gemcitabine, into solid lipid nanoparticles. GemC18-SLNs, when administered intravenously, showed strong antitumor activity against various human and mouse tumors in mouse models...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29163710/combination-of-histoculture-drug-response-assay-and-qpcr-as-an-effective-method-to-screen-biomarkers-for-personalized-chemotherapy-in-esophageal-cancer
#7
Bin Wei, Jiru Wang, Xiaohui Zhang, Zhaoye Qian, Jingjing Wu, Yuan Sun, Qin Han, Li Wan, Jing Zhu, Yong Gao, Xiaofei Chen
Personalized chemotherapy with the use of biomarkers helps to maximize clinical efficiency. Therefore, the present study aimed to identify a potential method for identifying biomarkers in esophageal cancer. A total of 49 freshly resected tumor tissues and 72 paraffin-embedded specimens from patients with esophageal cancer were obtained. mRNA expression levels of ERCC1, BRCA1, TUBB3, FBW7, RRM1, MDM2, TS and TOP1 were measured quantitative reverse transcription polymerase chain reaction (RT-qPCR). In vitro chemosensitivity to cisplatin, docetaxel, gemcitabine, etoposide, fluorouracil and irinotecan were tested using histoculture drug response assay (HDRA)...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29162142/-heatpac-a-phase-ii-randomized-study-of-concurrent-thermochemoradiotherapy-versus-chemoradiotherapy-alone-in-locally-advanced-pancreatic-cancer
#8
Niloy Ranjan Datta, Bernhard Pestalozzi, Pierre-Alain Clavien, Alexander Siebenhüner, Emsad Puric, Shaka Khan, Christoph Mamot, Oliver Riesterer, Jürg Knuchel, Cäcilia Sophie Reiner, Stephan Bodis
BACKGROUND: Pancreatic cancer has a dismal prognosis with 5-year overall survival rate of around 5%. Although surgery is still the best option in operable cases, majority of the patients who present in locally advanced stages are deemed inoperable. Novel approaches are therefore needed for the management of around 80% of these inoperable locally advanced pancreatic cancers (LAPC). Hyperthermia (39-43 °C) is a potent radiosensitizer and further enhances the action of gemcitabine, also a known radiosensitizer...
November 21, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29162047/treatment-recommendations-within-the-leeway-of-clinical-guidelines-a-qualitative-interview-study-on-oncologists-clinical-deliberation
#9
I Otte, S Salloch, A Reinacher-Schick, J Vollmann
BACKGROUND: Recommending the optimal treatment for an individual patient requires a well-balanced consideration of various medical, social and ethical factors. The interplay of these factors, interpretation of the patient's situation and understanding of the existing clinical guidelines can lead to divergent therapy recommendations, depending on the attending physician. Gaining a better understanding of the individual process of medical decision-making and the differences occurring will support the delivery of optimal individualized care within the clinical setting...
November 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29161926/neutrophil-lymphocyte-ratio-platelet-lymphocyte-ratio-neutrophil-platelet-score-and-prognostic-nutritional-index-do-they-have-prognostic-significance-in-metastatic-pancreas-cancer
#10
Mutlu Dogan, Efnan Algin, Zeynep Tugba Guven, Meltem Baykara, Tugba Fahriye Kos, Oznur Bal, Nurullah Zengin
INTRODUCTION: We aimed to evaluate the prognostic significance of neutrophil-lypmhocyte ratio (NLR), platelet-lymphocyte ratio (PLR), neutrophil-platelet score (NPS) and prognostic nutritional index (PNI) as proinflammatory markers in metastatic pancreas cancer (MPC). MATERIAL AND METHODS: 146 MPC patients followed-up at our center were evaluated retrospectively for clinicopathological characteristics and hematological ratios (NLR, PLR, NPS and PNI). PNI was calculated as [10 x serum albumin (g/dL)] + [0...
November 22, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29158911/a-retrospective-evaluation-of-activity-of-gemcitabine-platinum-regimens-in-the-treatment-of-recurrent-ovarian-cancer
#11
Tran N Le, Rachel E Harvey, Christine K Kim, Jubilee Brown, Robert L Coleman, Judith A Smith
Background: While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/carboplatin and gemcitabine/cisplatin have a similar ORR in separate clinical trials, the tworegimens have never been directly been compared. With overlapping dose-limiting toxicity of thrombocytopenia, the gemcitabine/carboplatin regimen has been challenging to employ in the clinical setting in previously treated ovarian cancer patients and is often associated with treatment delays and/or dose reductions...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/29158367/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-of-necuparanib-combined-with-nab-paclitaxel-and-gemcitabine-in-patients-with-metastatic-pancreatic-cancer-phase-i-results
#12
Eileen M O'Reilly, James Roach, Paul Miller, Kenneth H Yu, Catherine Tjan, Molly Rosano, Silva Krause, William Avery, Julie Wolf, Keith Flaherty, Darrell Nix, David P Ryan
LESSONS LEARNED: Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.Safety was documented, although dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity (cellulitis), and low-level anticoagulant effect. Nonetheless, the hypothesis of targeting prothrombotic pathways in pancreas adenocarcinoma remains compelling...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158123/efficacy-and-safety-of-necitumumab-continuation-therapy-in-the-phase-iii-squire-study-of-patients-with-stage-iv-squamous-non-small-cell-lung-cancer
#13
Tudor Ciuleanu, Mark A Socinski, Coleman Obasaju, Alexander V Luft, Aleksandra Szczesna, Wojciech Szafrański, Rodryg Ramlau, Beatrix Bálint, Olivier Molinier, Henrik Depenbrock, Shivani Nanda, Luis Paz-Ares, Nick Thatcher
INTRODUCTION: In a retrospective analysis of the SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) study, we investigated the efficacy and safety of single-agent necitumumab continuation therapy in patients with stage IV squamous non-small-cell lung cancer and in a subpopulation of patients with epidermal growth factor receptor (EGFR)-expressing tumors. PATIENTS AND METHODS: Patients were randomized 1:1 for ≤ 6 cycles of gemcitabine and cisplatin either with or without necitumumab...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29156703/preclinical-efficacy-of-the-novel-competitive-nampt-inhibitor-stf-118804-in-pancreatic-cancer
#14
Jair Machado Espindola-Netto, Claudia C S Chini, Mariana Tarragó, Enfeng Wang, Shamit Dutta, Krishnendu Pal, Debabrata Mukhopadhyay, Mauro Sola-Penna, Eduardo N Chini
NAD salvage is one of the pathways used to generate NAD in mammals. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in this pathway, uses nicotinamide (NAM) to generate nicotinamide mononucleotide (NMN). NMN is one of the main precursors of NAD synthesis in cells. Our previous study showed the importance of NAMPT in maintaining NAD levels in pancreatic ductal adenocarcinoma cells (PDAC), and that the NAMPT inhibitor FK866 decreased pancreatic cancer growth. We now tested the effect of STF-118804, a new highly specific NAMPT inhibitor, in models of pancreatic ductal adenocarcinoma...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156697/exploring-brusatol-as-a-new-anti-pancreatic-cancer-adjuvant-biological-evaluation-and-mechanistic-studies
#15
Zheng Lu, Zheng-Quan Lai, Albert W N Leung, Po Sing Leung, Zhao-Shen Li, Zhi-Xiu Lin
Pancreatic cancer is highly resistant to chemotherapeutic agents and is known to have a poor prognosis. The development of new therapeutic entities is badly needed for this deadly malignancy. In this study, we demonstrated for the first time that brusatol, a natural quassinoid isolated from a Chinese herbal medicine named Bruceae Fructus, possessed potent cytotoxic effect against different pancreatic adenocarcinoma cell lines. Its anti-pancreatic cancer effect was comparable to that of the first-line chemotherapeutic agents such as gemcitabine and 5-fluorouracil, with a more favorable safety profile...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29155177/co-treatment-with-a-c1b5-peptide-of-protein-kinase-c%C3%AE-and-a-low-dose-of-gemcitabine-strongly-attenuated-pancreatic-cancer-growth-in-mice-through-t-cell-activation
#16
Susumu Ishiguro, Atsushi Kawabata, Alejandro Zulbaran-Rojas, Kelsey Monson, Deepthi Uppalapati, Naomi Ohta, Makoto Inui, Charalampos G Pappas, Andreas G Tzakos, Masaaki Tamura
Although gemcitabine is an effective chemotherapeutic for pancreatic cancer, severe side effects often accompany its use. Since we have discovered that locally administered C1B domain peptides effectively control tumor growth without any side effects, the efficacy of co-treatment with this peptide and a low dose of gemcitabine on the growth of pancreatic cancer was examined. Two- and three-dimensional cell culture studies clarified that a co-treatment with C1B5 peptide and gemcitabine significantly attenuated growth of PAN02 mouse and PANC-1 human pancreatic cancer cells in 2D and 3D cultures...
November 16, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29152553/oncological-outcomes-of-sequential-intravesical-gemcitabine-and-docetaxel-in-patients-with-non-muscle-invasive-bladder-cancer
#17
Niv Milbar, Max Kates, Meera R Chappidi, Filippo Pederzoli, Takahiro Yoshida, Alexander Sankin, Phillip M Pierorazio, Mark P Schoenberg, Trinity J Bivalacqua
Background: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). Objective: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies...
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29152166/a-retrospective-cohort-study-of-treatment-patterns-among-patients-with-metastatic-soft-tissue-sarcoma-in-the-us
#18
Victor M Villalobos, Stacey DaCosta Byfield, Sameer R Ghate, Oluwakayode Adejoro
Background: Since treatment patterns in metastatic soft tissue sarcoma (mSTS) have not been studied subsequent to US approval of pazopanib in 2012, this study sought to examine mSTS treatment patterns by line of therapy, including regimen and duration of therapy. Methods: This retrospective study employed administrative claims from a large US health plan from 1/2006-9/2015. Adult mSTS patients were required to have an NCCN-recommended therapy and be continuously enrolled in the health plan during the study period...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/29152071/outcomes-of-phase-i-clinical-trials-for-patients-with-advanced-pancreatic-cancer-update-of-the-md-anderson-cancer-center-experience
#19
Jennifer B Goldstein, Chad Tang, Kenneth R Hess, David Hong, Vivek Subbiah, Filip Janku, Siqing Fu, Daniel D Karp, Aung Naing, Apostolia Maria Tsimberidou, Jennifer Wheler, Ralph Zinner, Milind Javle, Gauri R Varadhachary, Robert A Wolff, David R Fogelman, Funda Meric-Bernstam, Sarina A Piha-Paul
Background: In 2011, we reported the outcomes of pancreatic cancer (PC) patients enrolled in phase I trials at our institution from 2004 through 2009. At the time, gemcitabine and erlotinib were the only Food and Drug Administration-approved drugs for PC and median overall survival (OS) from consultation in the phase I clinic was 5 months. We sought to determine the impact of novel therapeutics on PC patients in phase I trials. Methods: We reviewed records of PC patients treated in phase I trials at our institution from January 2009 through December 2014...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152060/inhibition-of-chk1-sensitizes-ewing-sarcoma-cells-to-the-ribonucleotide-reductase-inhibitor-gemcitabine
#20
Kelli L Goss, Stacia L Koppenhafer, Kathryn M Harmoney, William W Terry, David J Gordon
Ewing sarcoma is a bone and soft tissue sarcoma that occurs in children and young adults. The EWS-FLI1 gene fusion is the driver mutation in most Ewing sarcoma tumors and functions, in part, as an aberrant transcription factor. We recently identified that Ewing sarcoma cells are sensitive to inhibition of ribonucleotide reductase (RNR), which catalyzes the formation of deoxyribonucleotides from ribonucleotides. In this report, we show that Ewing sarcoma cells are sensitive to treatment with clofarabine, which is a nucleoside analogue and allosteric inhibitor of RNR...
October 20, 2017: Oncotarget
keyword
keyword
40281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"